关键词: Checklist Data set ICCR Paraganglioma Pheochromocytoma Structured report Synoptic reporting

Mesh : Adrenal Gland Neoplasms / pathology Carcinoma / pathology Humans Paraganglioma / pathology Pathology, Clinical / standards Pheochromocytoma / pathology Research Design / standards

来  源:   DOI:10.1016/j.humpath.2020.04.012   PDF(Sci-hub)   PDF(Pubmed)

Abstract:
The International Collaboration on Cancer Reporting (ICCR) is a not-for-profit to develop evidence-based, internationally agreed-upon standardized data sets for each anatomic site, to be used throughout the world. Providing global standardization of pathology tumor classification, staging, and other reporting elements will lead to improved patient management and enhanced epidemiological research.
Pheochromocytoma and paraganglioma are uncommon and are frequently overlooked in registry data sets. Malignant criteria have previously been defined only when there was metastatic disease.
With recent recognition of a significant inheritance association and the development of risk stratification tools, this data set was created in order to obtain more meaningful outcomes and management data, using similar criteria across the global pathology community. Issues related to key core and non-core elements, especially clinical hormonal status, familial history, tumor focality, proliferative fraction, adverse or risk stratification features, and ancillary techniques, are discussed in the context of daily application to these types of specimens.
The ICCR data set, developed by an international panel of endocrine organ specialists, establishes a pathology-standardized reporting guide for pheochromocytoma and paraganglioma.
摘要:
国际癌症报告合作组织(ICCR)是一个非营利性组织,旨在开发循证医学,每个解剖部位的国际商定的标准化数据集,在世界各地使用。提供病理肿瘤分类的全球标准化,分期,和其他报告要素将导致改善患者管理和加强流行病学研究。
嗜铬细胞瘤和副神经节瘤并不常见,在注册数据集中经常被忽视。以前只有在有转移性疾病时才定义恶性标准。
随着最近对重要遗传关联的认识和风险分层工具的发展,这个数据集的创建是为了获得更有意义的结果和管理数据,在全球病理学界使用类似的标准。与关键核心和非核心要素有关的问题,尤其是临床荷尔蒙状态,家族史,肿瘤病灶,增殖分数,不利或风险分层特征,和辅助技术,在这些类型的标本的日常应用的背景下进行讨论。
ICCR数据集,由国际内分泌器官专家小组开发,建立嗜铬细胞瘤和副神经节瘤的病理学标准化报告指南.
公众号